An interventional study of Fospropofol (Lusedra®) 6.5 and Fospropofol (Lusedra®) 10 in Interstitial Cystitis, sponsored by Grace Shih, MD. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-10-03.
Sponsored by Grace Shih, MD · Not applicable, Interventional, and Treatment
Interstitial cystitis is a condition where a defect in the protective lining of the bladder causes the urinary symptoms such as urgency, frequency and pain/burning on urination. One way to help ease the symptoms of this disease is to fill the bladder full of water every 4 to 6 months.
Since this is a painful procedure an anesthesiologist will give you a drug that will make you unconscious for the procedure. General anesthesia can be given to you through an IV tube that is placed in a vein in your arm. There are only a few agents that induce sedation and these agents have certain disadvantages such as waking up slowly, low blood pressure, and pain at the injection site and a prolonged time to consciousness.
This study will be comparing doses of a new IV sedation induction agent drug to put you to sleep called fospropofol (Lusedra®).
235 studies on the registry are indexed under Cystitis; 22 are open to participants now.
Browse Cystitis studies →Grace Shih, MD is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Male or female outpatients
-> 18-65 years of age,
Exclusion criteria are:
Drug: Fospropofol (Lusedra®) 6.5
Drug: Fospropofol (Lusedra®) 10
Drug: Fospropofol (Lusedra®) 12
Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
To evaluate the differences in dose on the time to loss of consciousness and loss of reflex using the laryngeal mask airway (LMA).
To evaluate the use, dosing, efficacy and safety of fospropofol (Lusedra®) for the induction of general anesthesia using the laryngeal mask airway (LMA) in outpatient urology patients receiving hydrodilation therapy.
Time frame: 1 day
To evaluate the difference in dose on blood pressure and heart rate using the laryngeal mask airway (LMA)
Time frame: 1 day
No study locations are listed for this record.
This study is withdrawn, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Grace Shih, MD